The Mainz-based biotech company, Biontech has taken one more important hurdle on the way to the development of a vaccine against Sars-CoV-2. How does the company communicate together with the American pharmaceutical company Pfizer, with the Biontech in Germany and in the United States work together, have two of the four vaccine candidates from the American health authority FDA granted Fast-Track Status. The Biontech-share gains in the face of the message in the course of trade of more than ten percent.
by Daniel Schleidt
editor in the Rhein-Main-Zeitung.
F. A. Z. Twitter
as a result, the time-consuming approval procedures, the vaccines will need to go through is accelerated. The Fast-Track process aims to support the development of new drugs and vaccines intended for the treatment or prevention of serious diseases and have the Potential to address a high unmet medical need.
“milestone”
The Status was on the basis of preliminary study data from Germany and the United States issued. We will continue to work closely with the FDA to accelerate the clinical development of a vaccine against the Coronavirus, said Özlem Türeci, Chief Medical Officer of Biontech.
